Until November, Quantum Surgicalspecialized in medical technologies and based in Montpellier, was awarded last November by the National Institute of Industrial Property (Inpi) in the start-up category.
This distinction highlights the remarkable progress of the young company, particularly with its system Epione®which redefines interventional oncology practices.
Epione®technology at the service of precision
Epione® is a solution that combines advanced robotics and image fusion. It allows clinicians to target and treat difficult-to-access tumors with unparalleled precision, particularly in abdominal cancers.
“Epione® promotes a minimally invasive treatment that burns tumors a few millimeters using a proven technique called percutaneous ablation.”
Bertin Nahum, CEO de Quantum Surgical
This technology is based on image-guided robotics, a principle similar to that of GPS. This innovation allows the practitioner to precisely navigate a complex environment, such as soft tissue, which is constantly deforming due to the body’s natural movements, such as breathing.
Developed over seven years, the system is now operational in several countries, notably in France, the United States, England and Germany.
To date, more than 700 patients have benefited from this technology, which allows early treatment of abdominal, lung and, soon, bone cancers.. “Our strategy is to expand to different parts of the body,” reveals Bertin Nahum.
A promising future
The INPI recognition underlines the importance of innovation in Quantum Surgical’s strategy. With an active patent filing policy, the start-up secures its technological advances and asserts itself as a key player in the medical robotics.
The company is also continuing its efforts to conquer new markets and expand the applications of its technology, while ensuring that innovation remains at the service of practitioners.
“The robot is not intended to replace the practitioner, but to help him or her provide better patient care.”
Bertin Nahum
In just a few years, Quantum Surgical has managed to transform an idea into an internationally recognized innovation. The company offers a revolutionary solution for the treatment of cancers that not only improves clinical outcomes, but also patients’ quality of life.